ARDM

  0%
Previous Close
Open
Price To Book
Market Cap
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

SEC filingsSee all SEC filings

  1. 8-K - Current report 19623750
  2. 8-K - Current report 19613046
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606075
  4. 8-K - Current report 19549335
  5. 8-K - Current report 19525691

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval granted July 16, 2009.
Sumavel
Migraine
Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).

SEC Filings

  1. 8-K - Current report 19623750
  2. 8-K - Current report 19613046
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606075
  4. 8-K - Current report 19549335
  5. 8-K - Current report 19525691
  6. 8-K - Current report 19520953
  7. 8-K - Current report 19516578
  8. S-1 - General form for registration of securities under the Securities Act of 1933 181212039
  9. RW - Registration Withdrawal Request 181205127
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181187037